Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

37 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Is CAR T a drug or a therapeutic pathway? Intention to treat versus per protocol analysis of real world studies of CAR-T cell therapy in relapsed refractory diffuse large B cell lymphoma.
Di Staso R, Casadei B, Locke FL, Jain M, Voorhees TJ, Kittai AS, Bastos-Oreiro M, Gutiérrez A, Martin Garcia-Sancho A, Terol MJ, Mead M, Maranzano MJ, Iacoboni G, Barba P, Kwon M, Bailen R, Reguera-Ortega JL, Mian A, Hill B, Bachy E, Morschhauser F, Houot R, Thieblemont C, Le Gouill S, Masetti R, Gori D, Broccoli A, Zinzani PL, Argnani L. Di Staso R, et al. Among authors: martin garcia sancho a. Blood Cancer J. 2024 Nov 7;14(1):197. doi: 10.1038/s41408-024-01183-8. Blood Cancer J. 2024. PMID: 39511146 Free PMC article. No abstract available.
Integrative single-cell multi-omics of CD19-CARpos and CARneg T cells suggest drivers of immunotherapy response in B cell neoplasias.
Guerrero-Murillo M, Rill-Hinarejos A, Trincado JL, Bataller A, Ortiz-Maldonado V, Benítez-Ribas D, Español-Rego M, González-Navarro EA, Martínez-Cibrián N, Marchese D, Martín-Martín L, Martín García-Sancho A, Rives S, Heyn H, Juan M, Urbano-Ispizúa Á, Delgado J, Orfao A, Mereu E, Bueno C, Menendez P. Guerrero-Murillo M, et al. Among authors: martin garcia sancho a. Cell Rep Med. 2024 Nov 19;5(11):101803. doi: 10.1016/j.xcrm.2024.101803. Epub 2024 Oct 28. Cell Rep Med. 2024. PMID: 39471818 Free article.
Development and validation of the post-CAR prognostic index for large B-cell lymphoma patients after CAR-T progression in third or later line treatment.
Iacoboni G, Navarro V, Sesques P, Rejeski K, Bastos-Oreiro M, Serpenti F, Martin Lopez AA, Iraola-Truchuelo J, Delgado J, Perez A, Guerreiro M, Caballero AC, Martinez-Cibrian N, Luzardo Henriquez H, Sanchez Pina JM, Sancho JM, Ghesquieres H, Mussetti A, Lopez Corral L, Hernani R, Reguera JL, Sureda A, Bosch F, Martin Garcia-Sancho A, Kwon M, Subklewe M, Kuhnl A, Bachy E, Barba P, Villacampa G, Abrisqueta P. Iacoboni G, et al. Among authors: martin garcia sancho a. J Hematol Oncol. 2024 Oct 29;17(1):102. doi: 10.1186/s13045-024-01608-8. J Hematol Oncol. 2024. PMID: 39468591 Free PMC article.
Phase 2 trial of the farnesyltransferase inhibitor tipifarnib for relapsed/refractory peripheral T-cell lymphoma.
Witzig T, Sokol L, Kim WS, de la Cruz Vicente F, Martín García-Sancho A, Advani R, Roncero Vidal JM, de Oña Navarrete R, Marín-Niebla A, Rodriguez Izquierdo A, Terol MJ, Domingo-Domenech E, Saunders A, Bendris N, Mackey J, Leoni M, Foss F. Witzig T, et al. Among authors: martin garcia sancho a. Blood Adv. 2024 Sep 10;8(17):4581-4592. doi: 10.1182/bloodadvances.2024012806. Blood Adv. 2024. PMID: 38991123 Free PMC article. Clinical Trial.
Author Correction: Lisocabtagene maraleucel in follicular lymphoma: the phase 2 TRANSCEND FL study.
Morschhauser F, Dahiya S, Palomba ML, Martin Garcia-Sancho A, Reguera Ortega JL, Kuruvilla J, Jäger U, Cartron G, Izutsu K, Dreyling M, Kahl B, Ghesquieres H, Ardeshna K, Goto H, Barbui AM, Abramson JS, Borchmann P, Fleury I, Mielke S, Skarbnik A, de Vos S, Kamdar M, Karmali R, Viardot A, Farazi T, Fasan O, Lymp J, Vedal M, Nishii R, Avilion A, Papuga J, Kumar J, Nastoupil LJ. Morschhauser F, et al. Among authors: martin garcia sancho a. Nat Med. 2024 Aug;30(8):2374. doi: 10.1038/s41591-024-03175-4. Nat Med. 2024. PMID: 38982297 Free PMC article. No abstract available.
Ibrutinib in Combination with R-GemOx in Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma of Nongerminal Center B-cell-like Type: Phase II Clinical Trial of the Spanish GELTAMO Group.
Rey-Búa B, Grande C, Sánchez Blanco JJ, Abrisqueta P, Gutiérrez A, Ramírez Páyer Á, Giné E, Zeberio Etxetxipia I, Terol MJ, de la Cruz Vicente F, Andreu R, Ramirez MJ, de la Fuente A, Viguria MC, Peñarrubia MJ, Jiménez-Ubieto A, Montes-Moreno S, López-Guillermo A, Caballero MD, Martín García-Sancho A. Rey-Búa B, et al. Among authors: martin garcia sancho a. Clin Cancer Res. 2024 Sep 3;30(17):3704-3714. doi: 10.1158/1078-0432.CCR-24-0183. Clin Cancer Res. 2024. PMID: 38900037 Clinical Trial.
Lisocabtagene maraleucel in follicular lymphoma: the phase 2 TRANSCEND FL study.
Morschhauser F, Dahiya S, Palomba ML, Martin Garcia-Sancho A, Reguera Ortega JL, Kuruvilla J, Jäger U, Cartron G, Izutsu K, Dreyling M, Kahl B, Ghesquieres H, Ardeshna K, Goto H, Barbui AM, Abramson JS, Borchmann P, Fleury I, Mielke S, Skarbnik A, de Vos S, Kamdar M, Karmali R, Viardot A, Farazi T, Fasan O, Lymp J, Vedal M, Nishii R, Avilion A, Papuga J, Kumar J, Nastoupil LJ. Morschhauser F, et al. Among authors: martin garcia sancho a. Nat Med. 2024 Aug;30(8):2199-2207. doi: 10.1038/s41591-024-02986-9. Epub 2024 Jun 3. Nat Med. 2024. PMID: 38830991 Free PMC article. Clinical Trial.
Impact of the kinetics of circulating anti-CD19 CAR-T cells and their populations on the outcome of DLBCL patients.
Martín-Martín L, Gutiérrez-Herrero S, Herrero-García M, Martín García-Sancho A, Yeguas A, Martín-López AÁ, López-Corral L, Pérez-López E, García-Blázquez M, Sánchez-Guijo F, Vidriales MB, Gaipa G; INCAR consortium; EuroFlow consortium; Orfao A. Martín-Martín L, et al. Among authors: martin garcia sancho a. Blood Cancer J. 2024 May 17;14(1):83. doi: 10.1038/s41408-024-01065-z. Blood Cancer J. 2024. PMID: 38760376 Free PMC article. No abstract available.
New therapies for relapsed or refractory aggressive B-cell lymphoma increase survival: Analysis from the RELINF registry of the GELTAMO group.
Bastos-Oreiro M, Abrisqueta P, Gutierrez A, Jiménez Ubieto A, Poza M, Fernanez-Caldas P, LLacer MJ, Gonzalez de Villambrosia S, Córdoba R, López A, Ceballos E, Navarro B, Muntañola A, Donato E, Diez-Baeza E, Escoda L, Luzardo H, Peñarrubia MJ, García Belmonte D, Pardal E, Lozada C, Martín García-Sancho A. Bastos-Oreiro M, et al. Among authors: martin garcia sancho a. Hemasphere. 2024 Apr 22;8(4):e70. doi: 10.1002/hem3.70. eCollection 2024 Apr. Hemasphere. 2024. PMID: 38650598 Free PMC article. No abstract available.
37 results